Q. You recently wrote that testosterone does not increase the risk for heart attacks. But you overlooked the real risk of ...

Thousands of men with prostate cancer will be offered a life-extending drug on the NHS within weeks. For the first time patients whose prostate cancer has not spread will be able to receive the drug ...

Foresee Pharmaceuticals has shown that a long-acting version of its injectable prostate cancer med Camcevi can help patients with central precocious puberty (CPP), potentially opening the door | ...

LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health Canada in 1989 for advanced prostate cancer, and later for various ...

Treatment with Leuprorelin did not improve OS or disease-specific survival for patients with nonmetastatic, high-risk prostate cancer who have undetectable PSA levels, while causing more adverse ...

Q. You recently wrote that testosterone does not increase the risk for heart attacks. But you overlooked the real risk of ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...

In a previous study, the researchers showed that PSA scores can impact both doctor and patient behavior, leading to biopsy ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...